Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Multicenter Cytomegalovirus (CMV) Specific Immune Monitoring to Predict Patient Risk After Lung Transplantation (CTOT-22)

NCT03300882 is registered in ClinicalTrials.gov with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor.

NCT NCT03300882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03300882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Multicenter Cytomegalovirus (CMV) Specific Immune Monitoring to Predict Patient Risk After Lung Transplantation (CTOT-22)
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Phase
Observational
Overall status
Completed
Start date
October 31, 2017
Completion date
November 25, 2019
Enrollment
84 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

lung transplant